Open access · US-GOV
via ClinicalTrials.gov Clinical trial
Sorafenib in Elderly Patients With Metastatic Renal Cell Carcinoma (SERCC Study) Impact of Adverse Events Management in Elderly mRCC Patients Treated With Sorafenib
Authors not listed
Centro di Riferimento Oncologico - Aviano · 2010
Abstract
Study Design This is a multicenter, open label, first line phase II study in elderly (≥ 65 years old) metastatic Renal Cell Carcinoma (mRCC) patients not suitable for any other currently approved treatment (bevacizumab+INF, cytokines or sunitinib) except for sorafenib.
Each patient treated with sorafenib enrolled in the study will be trained to observe the management tool for skin care. A study period of 3 years was estimated as follows: an enrollment period of 24 months and a further follow-up period of 12 months.
Objectives of the trial Primary objective The primary aim of this trial is the evaluation of the efficacy of a patient education program in the reduction of Hand-Foot Skin Reaction (HFSR).
Secondary Objectives
TO assess:
* The frequency of dose discontinuation, interruption and reduction
* The incidence of any grade diarrhoea, and other adverse events
* The overall Response Rate according to the RECIST criteria.
* Progression free survival (PFR) in study population and comparison of PFS between age sub groups in the current study population
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- ClinicalTrials.gov
- Canonical
- link ↗
- Fetched
- 2026-11-14 MST
Cite this
APA
Anonymous. (2010). Sorafenib in Elderly Patients With Metastatic Renal Cell Carcinoma (SERCC Study) Impact of Adverse Events Management in Elderly mRCC Patients Treated With Sorafenib. <em>Centro di Riferimento Oncologico - Aviano</em>. https://clinicaltrials.gov/study/NCT01342627
Vancouver
Anonymous. Sorafenib in Elderly Patients With Metastatic Renal Cell Carcinoma (SERCC Study) Impact of Adverse Events Management in Elderly mRCC Patients Treated With Sorafenib. Centro di Riferimento Oncologico - Aviano. 2010.
BibTeX
@misc{anon2010Sorafe,
title = {Sorafenib in Elderly Patients With Metastatic Renal Cell Carcinoma (SERCC Study) Impact of Adverse Events Management in Elderly mRCC Patients Treated With Sorafenib},
author = {Anonymous},
journal = {Centro di Riferimento Oncologico - Aviano},
year = {2010},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
University Hospital Freiburg 2023
Open access · US-GOV
Age-adjusted High-dose Chemotherapy Followed by Autologous Stem Cell Transplantation or Conventional Chemotherapy With R-MP as First-line Treatment in Elderly Primary CNS Lymphoma Patients - a Randomized Phase III Trial
Weprom 2020
Open access · US-GOV
Feasibility of an Adapted Physical Activity Program for Patients Treated With an Autologous Hematopoietic Stem Cell Transplantation
Zhejiang Cancer Hospital 2024
Open access · US-GOV
Sintilimab After Concurrent Chemoradiotherapy in Elderly Patients With Unresectable Esophageal Squamous Cell Carcinoma: A Randomized, Multi-center Phase II Clinical Trial
Gustave Roussy, Cancer Campus, Grand Paris 2013
Open access · US-GOV
Multicentric Randomized Phase III Trial Comparing Methotrexate and Cetuximab in First-line Treatment of Recurrent and/or Metastatic Squamous Cell Head and Neck Cancer in Elderly Unfit Patients According to Geriatric Evaluation
Soonchunhyang University Hospital 2021
Open access · US-GOV
A Pragmatic Randomized Clinical Trial: Twice-weekly vs Thrice-weekly Incident hemoDialysis in Elderly Patients
Meir Medical Center 2017
Open access · US-GOV